Techfields   Report issue

For profit Phase 2 Phase 3
Founded: Suzhou China (2004)
Status: No NME R&D (2004)

Organization Overview

First Clinical Trial
2014
NCT02067611
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Jiangsu XinChen-Techfields Pharma Co., LTD. | lead institution | Techfields Inc | Techfields Pharma Co. Ltd | Tianjin XinChen-Techfields Pharma Co., LTD.

Active Ingredients

Drugs in Phase 3 Trials (1)

x0002 (4 trials)

Drugs in Phase 2 Trials (2)

ibuprofen (motrin) (2 trials)

tf0023 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cerebral Infarction (Phase 2)

Ischemia (Phase 2)

Osteoarthritis (Phase 3)

Osteoarthritis, Knee (Phase 3)

Osteoarthritis, Spine (Phase 3)

Stroke (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 3